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Abstract
The long-established application of rapid prototyping in additive manufactur-
ing (AM) has inspired a revolution in the medical industry into a new era, in which 
the clinical-driven development of the customized medical device is enabled. 
This transformation could only be sustainable if clinical concerns could be well 
addressed. In this work, we propose a workflow that addresses critical clinical 
concerns such as translation from medical needs to product innovation, anatomi-
cal conformation and execution, and validation. This method has demonstrated 
outstanding advantages over the traditional manufacturing approach in terms of 
form, function, precision, and clinical flexibility. We further propose a protocol for 
the validation of biocompatibility, material, and mechanical properties. Finally, we 
lay out a roadmap for AM-driven customized medical device innovation based on 
our experiences in Hong Kong, addressing problems of certification, qualification, 
characterization of three dimensional (3D) printed implants according to medical 
demands.
Keywords: hybrid additive manufacturing, customized medical device,  
anatomical conformation, personalized medicine
1. Introduction
Throughout the ages, medicine, by inherent definition, has always been focused 
on the treatment of persons and individuals. Whilst the pursuit of scientific prog-
ress has inexorably propelled this process toward a systematic and harmonized 
approach to treatments [1], the advent of personalized medical solutions has begun 
to reintegrate the personalized and idiosyncratic element to the therapeutic action 
[2, 3]. This has erupted into a vast and expansive medical discipline in the current 
day, ranging from diagnostic testing [4] to tailored drug treatments [5], to the 
customized medical devices that will be focal here. The orthopedic customized 
medical device has become one of the more mundane and immediately practical 
manifestations of personalized medicine.
Tunneling on customized prosthetic implants such as those in use in dental, 
maxillofacial, and orthopedic disciplines, the dichotomy between the conventional 
manufacturing technologies and additive manufacturing (AM) become apparent; 
where subtractive manufacturing and its kin excel in excellent control of repeatabil-
ity, scalability, surface finishing, and product proportions, the piecewise variation 
seen in personalized medical solutions levels the playing field significantly, so 
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much so that topologies unique to additive manufacturing (AM) processes such as 
freeform, anatomically compliant geometries and bioinductive honeycomb porous 
structures are allowed to shine through [6].
That being said, there are still substantial barriers between the current state of 
additive manufacturing and ancillary technologies, and mature, well-characterized 
medical applications [7]. Medical device development has and will for the fore-
seeable future be driven by clinical needs, and as medical device customization 
continues to progress, this personalized approach brings medical professionals ever 
closer to the engineering-based approaches used during the design and manufac-
ture of medical devices [8]. Operating in completely disparate paradigms, efficient 
bridging of this chasm will be imperative going forward [9].
Based in Hong Kong, the authors have been working toward the realization of 
streamlined AM utilization in the manufacture of customized medical devices over 
the past 5 years. Experience and involvement in the formulation of customized 
medical devices ranging from surgical guides and instruments to long-term ortho-
pedic implants have culminated in a relatively refined and progressively formulaic 
modus operandi. Putting forth a structured workflow and robust manufacturing 
process validation protocols, we look to initiate discussion in the space by this 
proof-of-concept, not in terms of technical operational detail but the constitution 
of the proposed system and its potency and soundness.
2. Additive manufacturing-assisted fabrication of the medical device
A typical workflow of preparing a customized medical device consists of 
four stages, namely, anatomic modeling, surgical planning and design, additive 
manufacturing, and postprocessing, as shown in Figure 1. This workflow has been 
testified and applied to fabricating 11 personalized surgical instruments in Hong 
Kong [10].
2.1 Anatomic modeling
Once clinical needs are identified, anatomical modeling is constructed based 
on the patient’s anatomy. Generic processes utilized during anatomical model-
ing are displayed in Figure 2. Computed tomography (CT) DICOM data is read 
as 2D grayscale pixel arrays arranged in a series of planes (Figure 2A). Desired 
anatomical structures are isolated on each individual array through intensity 
thresholding, artifacts, noise, and distortions are minimized by using image 
processing tools (Figure 2B). Series of 2D slice pixel arrays are interpolated and 
converted into a three dimensional (3D) computer-aided design (CAD)-friendly 
format (Figure 2C). These models and other patient information are the basis for 
surgical planning and design.
Figure 1. 
A typical workflow of preparing a customized medical device. Stage 1: anatomic modeling. Stage 2: surgical 
planning and design. Stage 3: additive manufacturing. Stage 4: postprocessing.
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2.2 Surgical planning and design
The surgical planning and design stage include an iterative process of (Figure 3A) 
surgical planning, (Figure 3B) CAD modeling, and (Figure 3C) computer-aided 
manufacturing (CAM) modeling, Figure 3. It requires immense communication 
between surgeons and engineers. The success of the design strongly depends on the 
level of details as well as the effectiveness of the communication of inputs from both 
parties. An example of surgical planning and design of a patient-specific instrument 
is presented in Figure 4.
2.3 Additive manufacturing
Proceeding from design to manufacturing, one AM method commonly used for 
a metal medical device is direct metal laser sintering (DMLS) under the powder bed 
fusion category. In a typical DMLS setup (LUMEX Avance 25, Matsuura), additive 
manufacturing is achieved by repeated procedures of (Figure 5A) recoating and 
(Figure 5B) laser sintering. The hybrid AM approach incorporates an additional 
procedure of (Figure 5C) computer numerical control (CNC) machining whenever 
several layers are built [11]. Here, we demonstrate the DMLS method by using 
cobalt-chromium alloy (Figure 5). Spherical powder of size ranges from 25 μm to 
40 μm (Koln3DCobaltChrome, Sandvik) is recoating onto the powder bed by a flat 
blade swiping sideways. The layer thickness is set at 0.4–0.5 mm whereas the laser 
power is set in the range of 100–400 W.
We examine the morphology and elemental composition of cobalt-chromium 
alloy before and after sintering. The morphology of cobalt-chromium alloy powder 
observed under field emission scanning electron microscope (FESEM) is shown 
in Figure 6a. The powder size ranges from 25 μm to 40 μm. After laser sintering, 
Figure 2. 
Stage 1: anatomic modeling, (A) scanning, (B) segmentation, and (C) construction of 3D model. Stage 2: 
surgical planning and design.
Figure 3. 




FESEM images. (a) Cobalt chromium alloy powder in size range of 25–40 μm. Scale bars are 100 μm (left) 
and 10 μm (right). (b) Surface of a part made by sintering of cobalt-chromium alloy. Scale bars are 100 μm.
Figure 5. 
Stage 3: additive manufacturing, (A) recoating, (B) laser sintering, and (C) CNC machining.
Figure 4. 
Surgical planning elements highlighted: segmented patient CT data (green) is combined with surgeon input 
(transparent yellow) culminating in customized surgical instrument (blue) and standardized implant (red).
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unsintered powder remains on the surface of the built part, as shown in Figure 6b. 
To improve the surface finishing of the AM product, postprocessing is required. 
Some AM parts undergo heat treatment to improve mechanical properties such as 
ductility and hardness.
Field emission scanning electron microscope/energy dispersive X-ray analysis 
(FESEM/EDX) was performed using an FEI Quanta 400 FEG MK2 electron micro-
scope and an AMETEK EDAX (PV776068-ME) X-ray analyzer to investigate the 
composition of the samples. The back-scattered electrons (BSE) images are formed 
by scanning the sample with a high-energy beam of primary electrons. The primary 
electrons interact with the sample and generate low-energy secondary electrons and 
back-scattered electrons, these electrons are collected, and the surface topography 
of the sample can be constructed. In addition to low-energy secondary electrons, 
X-rays are also generated by the interaction of the primary electrons and the sample. 
The characteristic of X-ray emission can give qualitative elemental information of the 
sample. In the present case, a standardless ZAF algorithm was used for quantification.
Elemental composition measurement is performed on the powder and the sintered 
part. The sintered samples used in this experiment undergo heat treatment processes. 
Main elements, such as cobalt (Co), chromium (Cr), and molybdenum (Mo), etc., 
are measured by EDX. We do not observe any significant changes in the elemental 
composition of cobalt-chromium alloy before and after the sintering process, which 
are in the form of powder and sintered parts, respectively, as shown in Figure 7. The 
result shows that the discrepancy in elemental composition varies by within ±2 wt%.
2.4 Postprocessing
Completing the AM process, postprocessing is performed for (Figure 8A) 
support removal and (Figure 8B) polishing according to the specific clinical needs, 
as illustrated in Figure 8. The postprocessing procedures are namely product-based 
plate detachment, support material removal, surface machining, and surface 
polishing. Even though a high degree of design complexity is enabled by AM 
Figure 7. 
Elemental composition of (a) cobalt-chromium alloy powder and (b) surface of the corresponding sintered 
part. Error bar is one standard deviation of five measurements.
Advanced Additive Manufacturing
6
technology, the low efficiency in postprocessing is a prevailing limiting factor in the 
entire process. To date, these postprocessing procedures are commonly conducted 
manually and relatively time-consuming depending on the complexity of the AM 
product. Recently, robotic control is introduced to automate the process and is 
gaining popularity in the manufacturing industry [12]. This technology is highly 
appealing to the medical industry for it possesses many advantages over manual 
operation such as higher accuracy and repeatability [13]. Full automation of robotic 
postprocessing systems is on its way to transforming the medical industry.
2.5 Case study
Here, we present a case study of a teenager with chondral lesions on the poste-
rior medial quadrant of the talar dome. The treatment was performed with the aid 
of medial malleolar osteotomy surgical jig (Figure 9). Our proposed workflow for 
the preparation of additive manufacturing-assisted fabrication of medical devices 
has been adopted.
A teenager patient admitted with severe ankle pain when walking was diag-
nosed with abnormalities on the posterior medial quadrant of the talar dome. The 
suspected cause of chondral lesion is vascularization defect in subchondral talar 
bone. The treatment approach is laid out by (1) medial malleolus removal with the 
surgical jig to expose chondral lesion, (2) removal of defective chondral tissue, (3) 
articular surface repair, and (4) reattachment of the medial malleolus.
With patient and regulatory approval, the medical device was prepared subse-
quently. In the stage of anatomical modeling, a CT scan of the ankle with slice thick-
ness 0.625 mm and slice resolution 0.5 mm was performed and the DICOM data 
of the talocrural joint were segmented and converted to surface mesh body. In the 
stage of surgical planning and device design, the chondral defect was first located. 
Cutting planes and fixation screw trajectories computationally were simulated and 
determined. Subsequently, guides for cutting planes and screw trajectories were 
designed, followed by patient-matched surface design according to anatomical 
landmarks and features coalesce to form the final design. Proceeding to the stage of 
additive manufacturing, the device was fabricated using a DMLS 3D printer with 
CoCrMo alloy (ASTM F-75 grade) powder. The process was validated with biocom-
patibility, mechanical, and compositional tests with critical dimensions verified. 
In the final stage of postprocessing, hot isostatic pressing (HIP) was performed to 
resolve residual stresses. After support removal, the device was ready for cleaning 
and packaging. The additive manufacturing-assisted fabrication of medial malleolar 
osteotomy surgical jig was completed.
Figure 8. 
Stage 4: postprocessing, (A) support removal, and (B) polishing.
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3. Critical clinical concerns in AM technology
3.1 Error of medical AM manufacturing
AM-assisted fabrication of the medical device is not an automatic process. The 
clinical data including anatomy and functions of the body parts need to be analyzed 
and segmentation of the relevant parts on the data source is of paramount impor-
tance to the beginning of every AM process.
Upon arriving at a diagnosis, with confirmation through medical imaging, the 
anatomical and functional data will be transformed from DICOM data to stereo-
lithography (STL) or CAD data formats interpretable by 3D printers. Engineers and 
clinicians will then corroboratively engage the design and customization effort. 
Given this approach, there are common pitfalls to take note of and avoid.
Figure 9. 
Case study: medial malleolar osteotomy surgical jig.
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3.1.1 Pathologies around the joint
In the case of a tumor around the hip joint, combined use of CT scan and 
magnetic resonance imaging (MRI) can help to create accurate models for surgical 
planning by coregistration of two sets of DICOM. The bony margins can be defined 
on a CT scan, whereas the soft tissue component of the tumor and sites of tumor 
invasion, periosteal elevation, and/or edema within the bone are best defined on 
MRI. A single model created using the information from both modalities allows the 
surgeon to plan resection and reconstruction utilizing all available information.
3.1.2 Quality of bones in the very young and very old
The differences in pixel density (on CT scan) or signal intensity (on MRI) 
between immature bones and cartilage and between osteoporotic bones and 
osteophytes and diseased tissues can be subtle. This is particularly challenging when 
dealing with complex pelvic pathology. It would need manual input to delineate 
osteophytes and osteopenic areas and pathology areas. This means that the surgeon, 
radiologist, or engineer will have to manually identify, at least in part, the various 
anatomic structures so they can be printed as separate objects. Segmented images 
designated for printing patient-specific models for surgical planning should be 
carefully reviewed before the AM manufacturing process and validated after 
removal of the disease body part.
The above list of conditions is not exhaustive which can cause a fundamental error 
to the final product with AM manufacturing process. An accurate translation from 
medical needs to product innovation is safeguarded by the effective communication 
and information exchange between various parties involved, as discussed in Section 2.
The understanding of various materials for the additive manufacturing process 
impacts the functionality of the final product. Training, technical competence, 
and experience utilizing medical software and software for 3D printers determine 
the quality of the object architecture. Clinical concerns in AM technology fall into 
the following categories—translation from medical needs to product innovation, 
anatomical conformation and execution, and validation.
The medical implants for the replacement of defective parts of the human 
anatomy can be validated with various means. One way is to scan the resected body 
part and overlay it with the source data of AM [14]. This will provide a quantitative 
measurement of the accuracy of pre- and postmanufacturing data.
3.2 Geometric conformity of AM medical devices
To investigate the geometric conformity of the AM parts, five distinct metallic med-
ical devices, namely jig 1, 2, and implant 1, 2, 3, have been made from the AM approach 
and 3D scanned. Turntable mode on Shining 3D Einscan Pro HD 3D scanner has been 
used to scan robotically milled product coated with AESUB blue scanning spray. The 
resultant model has then been matched and analyzed with corresponding functions in 
the materialize MIS 24 software suite. A clinically critical zone is defined for which the 
geometrical accuracy is examined. Overlaying the clinical critical surface area of the 
design model and the scanned model, a point-to-point spatial distance is measured for 
each point within the clinically critical zone. The average discrepancy and the discrep-
ancy histogram are presented in Table 1. Jig 1 yields the maximum average discrepancy 
of 0.13 ± 0.35 mm. For a typical computed tomography (CT) scan, the spatial and 
axial resolutions are 0.5 mm and 0.6 mm, which set the spatial accuracy requirement 
of the customized medical device. The result suggests that the AM-assisted fabrication 
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Time consumed per each of the four stages. Statistics of 11 cases. Error bars indicate the standard deviation.
3.3 Time consumed in each stage of AM-assisted fabrication
Apart from spatial resolution, the time consumed in AM-assisted fabrication 
is investigated. About 11 patient-specific instruments undertaking the proposed 
four-stage workflow being made, including five for hallux valgus osteotomy, four 
for high tibial osteotomy, one each for proximal femur osteotomy, and calcaneal 
osteotomy. A statistic of the time taken per each stage is measured, as shown in 
Figure 10. Among the cases reported, the average total time taken to complete the 
four stages is 3.3 ± 0.6 working days. The first and last stages, that is anatomical 
modeling and postprocessing, are relatively routine and typically take 0.5 days to 
complete. Contrarily, the time is taken for surgical planning and design (Stage 2) 
varies. Since Stage 2 involves an iterative process requiring communication between 
surgeons and engineers, the time involved is not only dependent on the complexity 
of the design but also the effectiveness of communication between different parties. 
As a result, time spent on Stage 2 has been found to be the lengthiest and the most 
variant. The time consumed in additive manufacturing (Stage 3) is dependent on 
the size and resolution of the AM part. Overall, the short time frame (in the order 
of a few days) to fabricate metallic patient-specific instruments by AM approach 
has brought numerous opportunities to cater for nonemergent clinical applications, 
such as osteotomy as demonstrated in this work.
4. Protocol for validation
While validation is a procedurally quintessential part of a fabrication that 
ensures process compatibility with intended product applications, it is especially 
imperative when dealing with medical devices that inherently possess the risks 
involved with interacting directly with human physiology. To this end, regulatory 
bodies such as the US Food and Drug Administration (FDA), the Chinese National 
Medical Products Administration (NMPA), and the decentralized regulatory 
authorities under the European Commission have developed medical device clas-
sification systems that categorize devices in accordance with the risk, their respec-
tive intended applications bring with them. Whilst there are nuances between the 
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numerous classifications, medical devices are typically assessed according to their 
intended purpose or use, with the duration, invasiveness, reusability, sterility, 
and activeness being commonly scrutinized aspects that are used as indicators of 
the associated risk. Among medical devices, this is particularly heightened when 
concerning prosthetic implants that are invasive in nature and are often implicated 
in extremely prolonged physiological exposure during and after surgical proce-
dures. Knowing this, validation is an exceedingly risk-dependent procedure, and 
as such one should always keep in mind and analyze the intended purpose or use of 
a product, what the associated explicit and implied product requirements are, and 
if and how relevant AM processes could potentially impact the conformity to these 
requirements.
The traditional pharmaceutical process validation structure of installation 
qualification (IQ ), operational qualification (OQ ), and performance qualification 
(PQ ) is generally an effective methodology when transplanted into the context of 
AM processes. Originating from a similarly health-related industry, this does not 
significantly vary when being applied to the fabrication of medical devices, though 
there are indeed adjustments to accommodate for the aforementioned variation 
in associated risk inherent to the nature of the products in question. Defining the 
scope and breadth of the process validation will grant it greater clarity in the con-
siderations to be made and the extent of the validation activities to be performed. 
While we will continue mostly focusing on hybrid additive manufacture processes 
(CNC-DMLS), be mindful that the type and nature of the AM processes concerned 
will affect the complexity of respective validation activities.
Installation qualification (IQ ) is the ascertainment, through the documentation 
of objective evidence acquired through predefined verification methods, that all rel-
evant equipment and machinery, whether primary, auxiliary, or ancillary, has been 
installed in accordance with predetermined requirements or recommendations. 
In practice in terms of hybrid AM processes, this typically involves infrastructural 
checks on items and ancillary systems such as electrical supply, compressed air 
supply, inert gas supply, and chiller, information that is customarily provided by 
most equipment manufacturers. Equipment manufacturers will also commonly 
have supportive services surrounding these activities in the form of complete user 
documentation documents as well as site acceptance tests (SAT) to qualify the 
commissioning of the equipment. Calibration of all measurement devices used 
throughout verification processes occurring during the entire validation is also 
usually included as part of installation qualification. IQ validation activities for the 
production of medical devices do not deviate from these elements, though one small 
detail to take note of is that the biologically oriented verification processes taking 
place subsequently in OQ and PQ validations might not have calibration available 
as it is traditionally understood. Some examples of this include the chemical assays 
used to determine physiological chemical characteristics and the histological exami-
nations for assessing biological reactions toward materials. Whilst these evaluative 
processes are typically performed by accredited laboratories, verifications are done 
in-house should always have additional device accuracy verifications performed.
Operational qualification (OQ ) is the process that results in the establishment 
of equipment operational parameters, limits, conditions, and requirements that 
optimally are expected to result in products meeting and product specifications. 
Performance qualification (PQ ) builds on the findings of OQ validation, effectively 
stress testing the manufacturing process under simulated worst-case scenarios to 
ensure product specifications are met regardless, or those potential deviations and 
their respective rates of occurrence are acknowledged. Both OQ and PQ typically 
comprise a series of tests and verifications, as well as the documentation of all perti-




Flowchart of selection of biocompatibility tests.
parameters, their control, veracity, and repeatability, are first verified to safeguard 
the authenticity of the test environment. In the case of hybrid AM processes, this 
can range from laser control parameters such as laser power and path overlap to 
sintering chamber environmental conditions such as oxygen concentration, build 
plate temperature, and enclosure temperature. This includes verification of metal 
powders used, as well as processes used to handle said metal powders and their 
respective control parameters. Once all highlighted aspects of operational control 
have been verified, operational limits and conditions can then be established and 
tests can be conducted on products produced by using operational parameters 
across this range, with acceptance criteria enacted based on product specifications. 
Through data collection and trend analysis, one can deduce and provide justifica-
tion for the establishment of optimal operational parameters and conditions during 
product manufacture, and thus concludes OQ validation and moving on to PQ 
validation. In terms of hybrid AM processes, since there is not much variation when 
considering maximal system throughput and worst-case scenarios, PQ is often 
simply performed through periodically testing products manufactured at maximum 
printing load.
Nonmedical applications of hybrid AM processes will generally inspect for 
mechanical aspects such as strength and malleability, material properties such as 
product composition, grain structure, presence of impurities, as well as explicit 
elements of product specification such as product form and critical dimensions. 
While international standards concerning appraisal methodology of these quanti-
ties are well established from beyond the medical field, the uniqueness of medical 
devices applications often warrants their own testing methodology. For example, 
whilst bending strength and stiffness are well-characterized quantities in their own 
right, ISO 9585 and ASTM F382 both describe methodologies that are specific to 
bone plates.
In the case of medical devices, critical evaluative processes, standardized 
methodologies, and highly specific parameters for biocompatibility conformance 
have been outlined in the document series ISO 10993. In particular, Part 1 of ISO 
10993 systematically outlines by flowchart all considerations necessitated by 
regulatory bodies when assessing the risk associated with a medical device, echoing 
factors previously mentioned surrounding intended use or purpose such as duration 
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of use and invasiveness, but also taking into account the nature of physiological 
surfaces contacted as well as the characteristics of the device itself. Depending on 
the outcome of the evaluation, a range of endpoints of biological evaluation are 
recommended, indicating the types of tests required to demonstrate an affirmative 
biological evaluation (Figure 11).
Critical to the case of hybrid AM processes is the stipulation that evaluation is 
only necessary if there is no available preexisting biocompatibility data regarding 
materials involved in the manufacture of the product. Whilst customized medical 
devices are still somewhat of a novel therapeutic solution, functionally identical or 
similar products have long been in use and have been extremely well-characterized 
biocompatibility. The same can be said for material composition, where tradition-
ally subtractively manufactured equivalents are well defined in terms of bio-
compatibility. Since hybrid AM process fabricated products are homogenous and 
typically established metal alloys, combined with animal guidelines detailed in ISO 
10993-2, it can be expected that barring medical devices where material properties 
are completely novel with no biocompatibility data, most hybrid AM products 
will only require physical and chemical characterization, as well as cytotoxicity. 
In vitro cytotoxicity, one of the other more baseline biocompatibility evaluations 
required is established in Part 5 of ISO 10993, utilizing cell culture assays to gauge 
the viability of cell growth in the vicinity of the product, and serves as a catch-all 
gatekeeping evaluation that preliminarily judges feasibility of biological product 
applications. The procedures for chemical and physical characterization have been 
detailed in Parts 18 and 19 of ISO 10993, respectively, entailing extensive proce-
dural and testing standards and references by which to carry out testing. Both put 
emphasis on the risk-based approach of the characterization, deriving required 
tests from the inherent risk of application and intended use. In the case of custom-
ized medical devices produced by hybrid AM processes, chemical characterization 
typically comprises of immersion and corrosion tests, detailed in Part 15 of ISO 
10993, that seek to detect potentially hazardous metal ions, as well as extraction 
tests, found in Part 16 of ISO 10993, that identify organic compounds likely bio-
logically disruptive in nature. The physical characterization will heavily depend on 
the material in use, as well as the intended use of the product, but generally, hybrid 
AM customized medical products will make use of scanning electron microscopes 
(SEMs) to identify product material and demonstrate equivalence with known 






















Implant Tissue/bone <24 h × × × ×
24 h<, 
<30 days
× × × × o × o
>30 days × × × × o × o
External 
brace
Intact skin <24 h × × × ×
24 h<, 
<30 days
× × × ×
>30 days × × × ×
×: tests in ISO standard are recommended if no preexisting marketed equivalents exist.
o: particular tests in ISO standard are recommended if no preexisting marketed equivalents exist.
Table 2. 
Biocompatibility tests required for 2 types of example medical devices.
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On the flip side, if the application and/or material in use is truly novel with 
insufficient precedent data for biocompatibility evaluation, a wide range of costly 
in vitro and in vivo tests will be required to satisfy the requirements of ISO 10993. 
Assuming the case of orthopedic implants, in addition to previously mentioned 
physical, chemical, and cytotoxicity characterizations, sensitization and irritation 
tests (ISO 10993—Part 10), pyrogenicity and systemic, subacute, subchronic, and 
chronic toxicity tests (ISO 10993—Part 11), implantation tests (ISO 10993—Part 
6), as well as genotoxicity and carcinogenicity testing, will be required. Fortunately, 
this is not a common occurrence for hybrid AM products where precedent and 
equivalence are the norms (Table 2) [15].
5.  A roadmap for AM-driven customized medical device innovation in 
Hong Kong
As personalized medical solutions popularize across the globe, there has been a 
scramble from regulatory bodies in bringing patient-conforming medical devices 
under the scope of preexisting regulative structure. Given the uniqueness of certain 
anatomical features and the significant interpersonal variation that exists, by 
definition, these medical devices will have noticeable differences on a piece-by-
piece basis. This results in increased difficulty in quality control and subsequently, 
regulation since these devices intrinsically are never completely identical and thus 
one cannot demonstrate conformance to regulatory requirements through a sample 
device in the present when every following iteration of the device will inherently be 
different, with variation often being guided by the anatomical features of patients. 
To this end, regulators have taken similar, risk-based approaches in incorporating 
these elements into their respective frameworks. The discussion will focus on the 
globally preeminent regulatory bodies of USFDA and the national regulatory bodies 
under the European Commission, as well as the locally relevant NMPA of China.
Personalized medical devices are generally split into three groups of products 
by regulatory bodies, based on the resemblance of their respective intended uses 
and manufacturing models with conventional, mass-produced medical devices that 
regulatory bodies devise their systems around. Here, we must part with the ter-
minology of “Customized Medical Device” in favor of more precise language. The 
first group is referred to as adaptable medical devices (AMD) and are personalized 
medical devices that are mass manufactured as a series of compatible components 
and assemblies, only to be tailored to the patient’s unique requirements at the point 
of care, by medical professionals in accordance with their medical judgment as well 
as device guidelines. They are essentially mass-produced products with an element 
of personalization in their intended use and are usually treated as such by regula-
tory bodies, simply following standard device classification protocols to determine 
regulatory requirements. In fact, the European Medical Device Regulation (EU 
MDR), FDA, and NMPA all do not implement additional regulatory procedures 
with respect to this type of device. Some AM-produced products make use of this 
ease of control and regulation, where the device is comprised of standardized, 
mass-produced parts as well as a relatively small AM-produced component that 
conforms to a subsection of patient anatomy that typically sees greater variation 
and hence requires personalization [16].
The second group is described as patient-matched medical devices (PMD) 
and are characterized by a largely identical manufacturing process, as well as a 
design envelope that encapsulates and bounds potential design features, includ-
ing patient-specific features, and their potential variation. Significant portions of 
AM-produced medical devices will fall under this category, with products that have 
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slightly adaptive if not harmonized intended uses, indications, contraindications, 
and design envelopes, that are essentially functionally identical but are designed to 
cater to differing individual anatomies. The classification of PMDs is an adaptation 
that regulatory bodies have utilized in incorporating personalized medical devices, 
and by proxy AM products, into a simpler regulatory framework, where these 
devices are generally viewed in a similar fashion as conventional medical devices 
but may require additional documentation, justifications, and design controls to 
compensate for the increased risk brought on by potential variations in design. The 
NMPA, EU MDR, and FDA do not have any additional regulatory requirements 
with respect to “Patient-Matched Medical Devices,” however, the FDA has devel-
oped and issued a guidance document titled “Technical Considerations for Additive 
Manufactured Medical Devices” in 2017, such that whilst there is no additional 
explicit requirement, there is a baseline of expectation when putting forth AM 
products that the FDA assumes [17].
The final category is the most original and authentic to the idea of personalized 
medicine, that being custom-made medical devices (CMD). This refers to devices 
that, at the request or prescription of a medical professional, are truly made for only 
one particular individual and is generally targeted toward extremely rare conditions 
CMD PMD AMD
Intended use Intended for use only for 
a particular individual 
(including medical 
professionals), to 
address specific feature 
or condition of the said 
target individual
Intended for use on the 
specific patient, with 
certain features matched 
with said patient’s 
anatomical data, done so 
according to the design 
envelope.
Intended for general use, 
with device personalized 
during the application, 
according to assembly 
instructions









Production Unique, tailored Repeated validated 
























PMA (Class III/Class II),
510(k) approval
(Class I/Class II)






Notification to regulatory 
body for initial cases 















All information is highly generalized and will deviate from product to product.
Table 3. 
Personalized medical device classification and regulatory requirements.
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where it is unfeasible to market the device or high specific conditions where no 
singular adaptive design envelope could realistically cover all facets of device. As 
a result of this distinctive product design and intended use, the manufacturing 
process is often unique in its entirety. Curiously the definition extends from devices 
tailored toward patients to devices catering to the medical professionals treating the 
patient. Owing to its inherently flexible nature, AM processes are often involved in 
the production of these devices, foremost being custom-made orthopedic implants. 
To date most regulatory bodies have implemented special exemptions and require-
ments to allow the use of these devices, conceding that truly customized devices 
will have to be evaluated and accounted for outside the general regulatory system. 
Annex IX [18] within the EU MDR has very clear requirements for CMDs, that a 
specific statement shall be prepared for all CMDs expressing key information, as 
well as other ancillary requirements. The EU MDR also states that Class III implant-
able “Custom-Made Medical Devices” shall additionally be subject to the typical 
conformity assessment. Meanwhile, the NMPA regulates CMDs less stringently, 
where “Custom-Made Medical Devices” are allowed for use after notification with 
key information is sent and acknowledged by regulatory authorities, with the 
precondition that the CMDs is to undergo standard market clearance and approval 
as soon as clinical data and feedback following the initial utilizations allow for the 
registration of the CMD (Table 3) [19, 20].
6. Conclusions
The demand for a customized medical device is at an all-time high. Thanks to 
the accuracy and variety of form and function to attain intended biomechanical 
function with adequate biocompatibility, AM-assisted fabrication has profound 
advantages in clinical flexibility. This work has demonstrated with examples a 
framework of AM-assisted fabrication of metallic medical devices serving intended 
clinical needs within a suitable time frame. The AM-assisted fabrication platform 
established is potentially utilizable with synthesized biomaterials and pharmaceu-
tics [21]. Opportunities are gravitating to surgeons and researchers navigating to 
efficacious outcomes in clinical applications.
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